$38 Million Funding Boost for Breakthroughs: Freya Biosciences Secures CE-Ventures’ Support

CE-Ventures, the corporate venture capital platform of Crescent Enterprises, has invested $38 million in Freya Biosciences in a Series A funding round. Freya Biosciences is a biotech company specializing in women’s health, particularly in microbial immunotherapies for reproductive health conditions. This funding will support the development of Freya’s lead drug candidate, an investigational vaginal microbial immunotherapeutic targeting infertility in women. The funding will also drive the evolution of Freya’s data science platform, focusing on deep microbiome sequencing and immune biomarker profiling. The investment is part of CE-Ventures’ commitment to exploring innovative fields and its belief in the potential of microbial immunotherapies. Other investors in the funding round include Sofinnova Partners, OMX Ventures, and Angelini Ventures.